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Human haematopoietic prostaglandin D synthase (H-PGDS; EC 5.3.99.2)
produces prostaglandin D2, an allergic and inﬂammatory mediator, in mast cells
and Th2 cells. H-PGDS has been crystallized with novel inhibitors with half-
maximal inhibitory concentrations (IC50) in the low nanomolar range by the
counter-diffusion method onboard the Russian Service Module on the
International Space Station. The X-ray diffraction of a microgravity-grown
crystal of H-PGDS complexed with an inhibitor with an IC50 value of 50 nM
extended to 1.1 A ˚ resolution at 100 K using SPring-8 synchrotron radiation,
which is one of the highest resolutions obtained to date for this protein.
1. Introduction
Prostaglandin (PG) D2 is a lipid mediator related to immunity and
inﬂammation through the activation of two types of receptors, the
D-type prostanoid receptor (DP) and the chemoattractant receptor-
homologous molecule expressed on Th2 cells (CRTH2), and is known
to cause contractions in smooth muscle in the airway via DP and to
mediate the chemotaxis of eosinophils and basophils into the lung via
CRTH2 (Matsuoka et al., 2000; Hirai et al., 2001). Haematopoietic
PGD synthase (H-PGDS) is known to be expressed in mast cells,
antigen-presenting cells and Th2 lymphocytes (Lewis et al., 1982;
Tanaka et al., 2000) and produces PGD2 from cyclooxygenase-derived
PGH2, a common precursor of various PGs (Kanaoka & Urade,
2003). Nonsteroidal anti-inﬂammatory drugs such as indomethacin
and aspirin, both of which inhibit cyclooxygenase, suppress immune
and inﬂammatory reactions by decreasing the production of all types
of prostanoids, including cytoprotective and anti-inﬂammatory PGs,
and induce adverse effects (Takeuchi et al., 2001; Halter et al., 2001).
Therefore, H-PGDS-speciﬁc inhibitors are thought to be more useful
lead compounds for anti-allergic and anti-inﬂammatory drugs, espe-
cially for the treatment of asthma, by decreasing the signals of PGD2
mediated by both DP and CRTH2. Aritake et al. (2006) reported the
three-dimensional structure of human H-PGDS in complex with an
orally active H-PGDS-speciﬁc inhibitor, 4-benzhydryloxy-1-[3-(1H-
tetrazol-5-yl)-propyl]-piperidine (HQL-79), which acts as an anti-
allergic drug, and elucidated the binding mode of HQL-79 within the
catalytic pocket of H-PGDS. To develop more effective compounds,
we have designed several novel H-PGDS inhibitors using HQL-79 as
alead compound anddetermined their binding modes in theenzyme–
inhibitor complexes through high-resolution X-ray crystallographic
analyses. During a series of high-quality protein crystallization
experiments on the International Space Station (ISS) from 2003 to
2008 which were funded by the Japan Aerospace Exploration Agency
(JAXA), we focused on high-resolution crystallization and obtained
high-quality crystals of H-PGDS. In this report, we report the puri-
ﬁcation and microgravity crystallization and provide a summary of
the preliminary X-ray diffraction analysis of complexes of H-PGDS
with three novel inhibitors for use in designing drugs based on its
three-dimensional structure.2. Materials and methods
2.1. Protein expression and purification
Human H-PGDS was expressed recombinantly in Escherichia coli
and puriﬁed as described previously (Aritake et al., 2006). In brief,
E. coli BL21 (DE3) cells were transformed with the prepared plasmid
carrying the cDNA of human H-PGDS. After the cells had been
harvested, disrupted in phosphate-buffered saline by sonication and
centrifuged, the resultant soluble fraction was applied onto a gluta-
thione-Sepharose 4B column (GE Healthcare). H-PGDS bound to
the resin was eluted with 50 mM Tris–HCl pH 9.0 containing 10 mM
glutathione. As the preparation showed a broad band on native
PAGE analysis, we further puriﬁed H-PGDS by Mono-Q HR5/5
chromatography (GE Healthcare) with a sodium chloride gradient
from 0.1 to 0.2 M in 20 mM Tris–HCl at 293 K. H-PGDS eluted at
around 0.15 M sodium chloride and separated into three peaks. The
fractions from the ﬁrst peak were used for crystallization. The ﬁnal
puriﬁed sample of H-PGDS showed a single band on SDS–PAGE
under reducing conditions and native PAGE under nonreducing
conditions. H-PGDS was concentrated to 3.0 mg ml
1 in 50 mM Tris–
HCl pH 7.5 using a Centricon YM-10 membrane (10 000 nominal
molecular-weight limit; Millipore) and stored at 277 K. The protein
concentration was determined spectrophotometrically at 280 nm.
2.2. Inhibitors
HQL-79 was obtained from Cayman. Three H-PGDS inhibitors,
compounds A, B and C, were synthesized at the Osaka Bioscience
Institute. The formulae of the inhibitors are proprietary information.
The IC50 values of the inhibitors were measured to be 400, 50 and
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Figure 1
The setup and conﬁguration of the counter-diffusion crystallization device, a JAXA crystallization box (JCB). (a) Parts of the crystallization device before assembly. (b)
Outline of the assembled crystallization device for the microgravity experiment. It was mounted in an aluminium container, the Granada Crystallization Facility, and
launched to the ISS. (c) Sample loading and crystallization-device setup. (i) Preparation of solutions. The protein solution (4.0 mg ml
1 human H-PGDS with or without
0.5 mM inhibitor in 150 mM sodium chloride, 15% PEG 6000, 5 mM dithiothreitol, 5 mM glutathione, 1% dioxane, 0.5 mM magnesium chloride and 20 mM Tris–HCl pH 8.0)
and the precipitant solution (30% PEG 6000, 10 mM dithiothreitol, 10 mM glutathione, 1% dioxane and 1 mM magnesium chloride in 50 mM Tris–HCl pH 8.4) were
prepared. The gel-tubes, which were polymerized agarose gels in a piece of plastic tubing, were incubated in 15% PEG 6000 solution containing 10 mM dithiothreitol, 10 mM
glutathione, 2% dioxane, 1 mM magnesium chloride and 50 mM Tris–HCl pH 8.4 for 10 d before crystallization-device setup. (ii) Loading solutions and assembling the
crystallization device. The protein solution was loaded into a capillary (1). The top of the capillary was tentatively sealed with clay and the gel-tube was plugged into the end
of the capillary (2). The precipitant solution was loaded into the outer tube (3). The capillaries were inserted into the outer tube (4). The bottoms of the outer tubes were
covered with caps and the top of the capillaries were completely sealed with epoxy adhesive (5).4400 nM, respectively, as described previously (Aritake et al., 2006).
The inhibitory effects of these inhibitors were stronger than that of
HQL-79 (IC50 = 5900 nM; Aritake et al., 2006).
2.3. Crystallization
H-PGDS was crystallized in a microgravity environment at 293 K
inside a Thermal Electric Biological Universal incubator onboard
the Russian Service Module on the ISS using JAXA’s microgravity
crystallization experiments JAXA-NGCF#1 and JAXA-NGCF#2 for
12 weeks from January to April 2007 and for 11 weeks from August to
October 2007, respectively.
For the JAXA microgravity experiments, we adopted the JAXA
Crystallization Box (JCB) as a crystallization device (Tanaka et al.,
2004a), which is a modiﬁcation of the original capillary counter-
diffusion method (Garcı ´a-Ruiz & Moreno, 1994; Garcı ´a-Ruiz, 2003;
Ng et al., 2003; Gonzalez-Ramirez et al., 2008; Ota ´lora et al., 2009).
The set-up conﬁguration of the JCB is shown in Fig. 1. The crystal-
lization condition was ﬁxed to start after the samples had been placed
in the microgravity environment (about 10 d after sample loading) by
adjusting the precipitant concentration and the gel-tube length. A
microseeding technique was applied as follows: small crystals of
H-PGDS were crushed in 5 ml twofold-diluted precipitant solution
and diluted 100-fold with the precipitant solution; 1 ml of the micro-
seed solution was then added to 11 ml protein solution. The number
of capillaries for each H-PGDS inhibitor is shown in Table 1. The
same crystallization condition was applied in the terrestrial control
experiment.
2.4. Data collection
Diffraction data were collected at 100 K with an X-ray wavelength
of 0.85 A ˚ on the BL41XU beamline at SPring-8, Harima, Japan using
an ADSC315 detector system. The crystals grown in the capillaries
were extracted into artiﬁcial mother liquor (30% PEG 6000, 10 mM
dithiothreitol, 10 mM glutathione, 1% dioxane and 1 mM magnesium
chloride in 50 mM Tris–HCl pH 8.4). The concentration of PEG 6000
in the artiﬁcial mother liquor was calculated using a one-dimensional
simulation program that estimates the time-course of the concen-
tration change of the precipitant solution at a certain position in the
capillary (Tanaka et al., 2004a). The method of harvesting crystals has
been reported previously (Tanaka et al., 2007). One crystal was
selected with a nylon loop, brieﬂy dipped into artiﬁcial mother liquor
supplemented with 15% glycerol as a cryoprotectant for less than 10 s
and plunged into a nitrogen-gas stream at 100 K. A total of 180
frames were collected using a crystal-to-detector distance of 150 mm
with 1 oscillation. The diffraction images were integrated and scaled
using the programs DENZO and SCALEPACK from the HKL-2000
suite (Otwinowski & Minor, 1997). We performed X-ray diffraction
experiments on two or three crystals and summarize the best data for
each complex in Table 1. Data sets were collected to the resolution
range where I/(I) > 2 and Rmerge < 50%.
3. Results and discussion
3.1. Visual inspection of crystals
Two or three crystals grew in every 10 mm of the capillaries both
on terra ﬁrma and in microgravity. The dimensions of the crystals
grown terrestrially and in microgravity were almost the same (0.3 
0.1  0.05 mm). However, the crystals grown in microgravity did not
form clusters (Fig. 2), suggesting that the crystal quality was improved
by crystallization in microgravity. The number and size of the crystals
did not change in the presence or the absence of H-PGDS inhibitors.
3.2. X-ray diffraction
The results of the X-ray diffraction are summarized in Table 1. All
crystals chosen for diffraction data collection were of sufﬁcient size
and of good quality as judged by visual inspection. In the counter-
diffusion method, crystals of better quality tend to grow at the
opposite side to the gel-tube, in the section of the capillary where the
concentration change of the precipitant is slower (Lopez-Jaramillo et
al., 2003). As a result, the crystals grown in capillaries at 30–40 mm
from the gel-tube of the capillary were used for X-ray diffraction
experiments in most of the cases. To avoid ﬂuctuations in the data
caused by crystal size differences, we chose microgravity-grown and
terrestrial-grown crystals of the same size for X-ray diffraction
experiments. Crystals of different space groups (P1) were obtained in
the presence of inhibitors, owing to the binding of the inhibitor,
compared with those grown in the absence of inhibitors (P21).
Terrestrial-grown crystals of H-PGDS in the presence of inhibitor
B and HQL-79 exhibited X-ray data sets to 1.8 and 1.5 A ˚ resolution
with mosaicities of 0.81 and 1.28, respectively (Table 1). Although the
H-PGDS crystals grown in the absence of inhibitor (space group P21)
and in the presence of inhibitors A and C showed X-ray diffraction to
1.7, 2.0 and 2.0 A ˚ resolution, respectively, we did not collect their
X-ray data sets because of relatively high mosaicity or poor-quality
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Table 1
Summary of X-ray diffraction experiments on H-PGDS crystals.
The best data from two or three X-ray diffraction analyses of each H-PGDS–inhibitor complex are shown in the table. The data set was collected to the resolution range at which
I/(I) >2 and Rmerge < 50%.
Unit-cell parameters Maximum resolution (A ˚ )
Inhibitor
IC50
(nM)
Space or
ground
No. of
capillaries
Crystal dimensions
(mm)
Position in the
capillary† (mm)
Space
group
a
(A ˚ )
b
(A ˚ )
c
(A ˚ )

()

()

()
Mosaicity
() Data set Observed
Free — Space 5 0.3  0.03  0.03 20–30 P21 48.5 47.3 184.3 90.0 97.0 90.0 0.54 1.5 1.5
Ground 5 0.3  0.02  0.02 30–40 P21 48.4 47.4 184.8 90.0 97.9 90.0 2.47 1.7 ‡
A 400 Space 3 0.3  0.1  0.05 30–40 P1 47.0 48.6 89.6 96.2 90.0 90.0 0.56 1.1 1.1
Ground 3 0.3  0.02  0.02 30–40 P1 48.8 47.2 93.4 87.1 80.1 90.1 3.39 2.0 ‡
B 50 Space 3 0.1  0.1  0.05 30–40 P1 46.9 48.2 89.4 83.9 90.0 90.0 0.62 1.1 1.1
Ground 3 0.1  0.1  0.05 30–40 P1 47.1 48.1 89.7 84.3 89.9 89.9 0.81 1.5 1.8
C 4400 Space 2 0.1  0.1  0.05 30–40 P1 46.9 48.0 88.9 84.3 89.9 89.9 1.48 1.4 1.8
Ground 2 0.1  0.1  0.05 30–40 § § § § §§§§ 2 . 0 §
HQL-79 5900 Space 2 0.3  0.1  0.05 30–40 P1 46.9 48.7 89.3 95.8 89.9 90.1 1.71 1.3 1.3
Ground 4 0.1  0.1  0.05 30–40 P1 47.0 48.3 89.2 95.7 90.2 89.9 1.28 1.5 1.5
† Position of the crystal from the bottom of the capillary. ‡ An X-ray diffraction data set was not collected because of high mosaicity. § An X-ray diffraction data set was not
collected because of the poor quality of the diffraction.diffraction. In contrast, microgravity-grown crystals in the absence or
the presence of inhibitors A, B, C and HQL-79 exhibited X-ray data
sets to 1.5, 1.1, 1.1, 1.8 and 1.3 A ˚ resolution with mosaicities of 0.54,
0.56, 0.62, 1.48 and 1.71, respectively (Table 1).
3.3. Affinity of inhibitors for H-PGDS
Among the microgravity-grown crystals, both the maximum reso-
lution and the mosaicity of the X-ray diffraction data are relatively
low in the complexes with inhibitors with low IC50 values (Table 1).
This may be a consequence of immobilization of the catalytic pocket
of H-PGDS after binding the high-afﬁnity inhibitors in the enzyme–
inhibitor complexes, leading to the growth of well ordered crystals in
microgravity.
Recently, novel inhibitors of H-PGDS have been generated by
fragment-based drug design and are expected to contribute to novel
drug development (Hohwy et al., 2008). The best inhibitor showed an
IC50 of 21 nM and is one of the most potent inhibitors described to
date. Such high-afﬁnity inhibitors may also improve the crystal
quality of H-PGDS–inhibitor complexes in the microgravity envir-
onment, as shown in this report.
3.4. The counter-diffusion method in microgravity
The counter-diffusion method used in this report is based on the
counter-diffusion of protein and precipitant along a capillary. Using
this method in a convection-free environment such as microgravity or
gels, uniform propagation of the supersaturation wave is expected in
the capillary, which enables simultaneous screening for optimal
conditions for protein crystallization. Moreover, in a convection-free
environment a protein-depletion zone (PDZ) and an impurity-
depletion zone (IDZ) are formed around the growing crystal, which
are believed to be beneﬁcial for improving crystal quality
(McPherson, 1999; Chernov, 1998; Thomas et al., 2000). In addition,
these zones are formed much more signiﬁcantly in a highly viscous
solution such as PEG (Tanaka et al., 2004b) and with highly puriﬁed
protein (Yamanaka et al., 2009). Since the numbers of crystals that we
have used here were very limited, we avoid any comparative state-
ments; however, these might have positive effects on the growth of
high-quality crystals in microgravity in our cases.
4. Conclusions
We obtained high-quality crystals of H-PGDS complexes with inhi-
bitors by the counter-diffusion method in a microgravity environ-
ment. The counter-diffusion method in microgravity is the only way
to obtain crystals of H-PGDS inhibitor complexes that diffract to 1.0–
1.5 A ˚ resolution. This will provide us with a better understanding of
the binding mode of H-PGDS with inhibitors for future drug design.
Structural reﬁnement is currently in progress.
It is still difﬁcult to identify any predictive technique to determine
whether a crystallization experiment will beneﬁt from microgravity;
however, many examples of improved crystal quality in microgravity
have been reported (Littke & John, 1986; DeLucas et al., 1989; Day &
McPherson, 1992; He & Carter, 1992; Borgstahl et al., 2001; Kundrot
et al., 2001; Sauter et al., 2001; Vergara et al., 2003; Snell & Helliwell,
2005; Evrard et al., 2007; Tanaka et al., 2007; Meyer et al., 2008). The
complexes of human H-PGDS with high-afﬁnity inhibitors are new
examples of improved crystal quality in microgravity.
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